Celgene Corp. (NASDAQ:CELG)‘s stock had its “buy” rating reaffirmed by investment analysts at Piper Jaffray Cos. in a research report issued to clients and investors on Tuesday.

Other analysts also recently issued research reports about the company. Argus reiterated a “buy” rating and issued a $155.00 price objective on shares of Celgene Corp. in a research report on Wednesday, September 7th. Cowen and Company reiterated a “buy” rating and issued a $150.00 price objective on shares of Celgene Corp. in a research report on Thursday, July 28th. Leerink Swann reiterated a “market perform” rating and issued a $135.00 price objective on shares of Celgene Corp. in a research report on Monday, September 12th. Stifel Nicolaus reiterated a “buy” rating and issued a $138.00 price objective on shares of Celgene Corp. in a research report on Tuesday, August 2nd. Finally, Vetr downgraded Celgene Corp. from a “hold” rating to a “sell” rating and set a $104.37 price objective for the company. in a research report on Monday, July 25th. Three equities research analysts have rated the stock with a hold rating and twenty-five have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $136.46.

Analyst Recommendations for Celgene Corp. (NASDAQ:CELG)

Shares of Celgene Corp. (NASDAQ:CELG) remained flat at $100.06 during trading on Tuesday. The company’s stock had a trading volume of 1,948,775 shares. The stock’s 50-day moving average price is $105.35 and its 200 day moving average price is $105.53. The firm has a market capitalization of $77.56 billion, a price-to-earnings ratio of 42.29 and a beta of 1.49. Celgene Corp. has a 52-week low of $93.05 and a 52-week high of $128.39.

Celgene Corp. (NASDAQ:CELG) last released its earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.39 by $0.05. The company earned $2.74 billion during the quarter, compared to the consensus estimate of $2.70 billion. Celgene Corp. had a return on equity of 67.06% and a net margin of 18.95%. Celgene Corp.’s quarterly revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS. On average, equities research analysts expect that Celgene Corp. will post $5.71 EPS for the current year.

In related news, Director Michael D. Casey sold 43,134 shares of the stock in a transaction dated Monday, August 22nd. The stock was sold at an average price of $114.01, for a total transaction of $4,917,707.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Robert J. Hugin sold 100,000 shares of the stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $110.00, for a total value of $11,000,000.00. Following the sale, the insider now owns 1,022,201 shares of the company’s stock, valued at approximately $112,442,110. The disclosure for this sale can be found here. 0.97% of the stock is owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the company. First Financial Corp IN boosted its stake in Celgene Corp. by 30.9% in the third quarter. First Financial Corp IN now owns 967 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 228 shares in the last quarter. Jolley Asset Management LLC boosted its stake in Celgene Corp. by 58.8% in the second quarter. Jolley Asset Management LLC now owns 1,215 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 450 shares in the last quarter. Smithfield Trust Co. boosted its stake in Celgene Corp. by 12.5% in the second quarter. Smithfield Trust Co. now owns 1,282 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 142 shares in the last quarter. Kings Point Capital Management boosted its stake in Celgene Corp. by 1.7% in the first quarter. Kings Point Capital Management now owns 1,316 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 22 shares in the last quarter. Finally, Integrated Investment Consultants LLC boosted its stake in Celgene Corp. by 21.8% in the second quarter. Integrated Investment Consultants LLC now owns 1,339 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 240 shares in the last quarter. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Celgene Corp. Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Receive News & Stock Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related stocks with our FREE daily email newsletter.